We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmaker Eli Lilly, in conjunction with World Tuberculosis (TB) Day, has announced plans to invest an additional $50 million in a global partnership to fight multidrug-resistant tuberculosis (MDR-TB).
The
U.S. Centers for Disease Control and Prevention (CDC) has adopted the recommendation of its Advisory Committee on Immunization Practices for the use of Merck's Gardasil quadrivalent human papillomavirus (HPV) vaccine in girls and women ages 11 to 26, Merck announced.
The European Medicines Agency (EMEA) has issued a statement on the safety of Tamiflu in response to news of neuropsychiatric adverse events reported in connection with the drug in Japan.
Cubist Pharmaceuticals announced it has entered into a license agreement with Merck for the development and commercialization of the antibiotic Cubicin in Japan.
In advance of World Tuberculosis (TB) Day later this week, the President's Emergency Plan for AIDS Relief (PEPFAR) announced it is planning to increase its response to tuberculosis globally by supporting programs that integrate HIV prevention, treatment and care with TB services.
In one year Canadians could save $700 million on the cost of
prescription drugs if the use of generic drugs were increased to U.S. levels, the Canadian Generic Pharmaceutical Association (CGPA) said in response to the 2006 Canadian prescription drug sales data released by IMS Health.
Sanofi-aventis announced that its weight-loss drug Acomplia has been added to the list of pharmaceutical products that are reimbursable under the French health system, as published in the Official Journal of the French Republic.
The U.S. FDA announced it has granted tentative approval to generic lamivudine tablets, 150 mg, manufactured by Matrix Laboratories under expedited-review provisions developed for the President's Emergency Plan for AIDS Relief (PEPFAR).
Pfizer announced yesterday that a federal court in New Jersey has upheld the company's three main U.S. patents covering Celebrex, a selective non-steroidal anti-inflammatory drug used to treat pain and inflammation.